Gilead Sciencesvs.Regeneron
GILD vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 2.3× larger than Regeneron by market cap; Regeneron trades at the lower P/E (15.7 vs 17.5); year to date, Gilead Sciences leads (+5.8% vs −13.9%).
Side by side
| GILD | REGN | |
|---|---|---|
| Market cap | $162B | $69.7B |
| Price | $129.83 | $664.52 |
| Today | −3.7% | −0.5% |
| Return YTD | +5.8% | −13.9% |
| Return 1Y | +13.3% | +18.7% |
| P/E | 17.5 | 15.7 |
| P/S | 5.4 | 4.7 |
| P/B | 6.9 | 2.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →More comparisons in Biotech & innovation
See where GILD and REGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →